title: Strategies toward optimization of the metabolism of a series of serotonin-4 partial agonists: investigation of azetidines as piperidine isosteres.
abstract: 1.The first generation 5HT-4 partial agonist, 4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol, PF-4995274 (TBPT), was metabolized to N-dealkylated (M1) and an unusual, cyclized oxazolidine (M2) metabolites. M1 and M2 demonstrated pharmacological activity at 5HT receptor subtypes warranting further investigation into their dispositional properties in humans; M2 was a minor component in vitro but was the pre-dominant metabolite identified in human plasma. 2.To shift metabolism away from the piperidine ring of TBPT, a series of heterocyclic replacements were designed, synthesized, and profiled. Groups including azetidines, pyrrolidines, as well as functionalized piperidines were evaluated with the goal of identifying an alternative group that maintained the desired potency, functional activity, and reduced turnover in human hepatocytes. 3.Activities of 4-substituted piperidines or pyrrolidine analogs at the pharmacological target were not significantly altered, but the same metabolic pathways of N-dealkylation and oxazolidine formation were still observed. Altering these to bridged ring systems lowered oxazolidine metabolite formation, but not N-dealkylation. 4.The effort concluded with identification of azetidines as second-generation 5HT4partial agonists. These were neither metabolized via N-dealkylation nor converted to cyclized oxazolidine metabolites rather oxidized on the isoxazole ring. The use of azetidine as a replacement for aliphatic aza-heterocyclic rings in drug design to alter drug metabolism and pharmacology is discussed.
authors.affiliation: a Department of Pharmacokinetics , Dynamics, and Metabolism , Groton , CT , USA.
authors.forename: Ronald Scott
authors.initials: RS
authors.lastname: Obach
authors.affiliation: b Department of Neuroscience Chemistry , Groton , CT , USA.
authors.forename: Erik A
authors.initials: EA
authors.lastname: LaChapelle
authors.affiliation: c Department of Neuroscience Medicinal Chemistry , Cambridge , MA , USA , and.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Brodney
authors.affiliation: a Department of Pharmacokinetics , Dynamics, and Metabolism , Groton , CT , USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Vanase-Frawley
authors.affiliation: a Department of Pharmacokinetics , Dynamics, and Metabolism , Groton , CT , USA.
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Kauffman
authors.affiliation: d Department of Pharmacokinetics , Dynamics, and Metabolism , Cambridge , MA , USA.
authors.forename: Aarti
authors.initials: A
authors.lastname: Sawant-Basak
mesh_terms: D001384:Azetidines / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology*; D012701:Serotonin / Q000378:metabolism*
chemical_list: D001384:Azetidines; D010880:Piperidines; D012701:Serotonin; C082735:azetidine
keywords: Alicyclic amine; azetidine; metabolism; piperidine